People flourish when all major aspects of their life are good, but a new global study suggests that isn't the case for young adults in many high-income countries. That surprised the study's co-lead.

Breakthroughs in age-related macular degeneration (AMD) treatments have revolutionized the management of this progressive and potentially devastating eye disease. These include treatments such as ...

Eylea, or aflibercept, had global sales of just under $10 billion in 2024, thanks to its strong competitive positioning and more attractive dosing regimen versus Lucentis and Avastin in ...

Regeneron reported quarterly revenue contraction of 4% year on year, which was largely driven by declines in its Eylea franchise. Original dose Eylea declined 39% year on year and 38% sequentially ...

AI-generated essays don't yet live up to the efforts of real students, according to new research from the University of East Anglia (UK). A new study published in Written Communication compared ...

This pattern has shown up yet again in a new study, one of a collection of papers published on Wednesday in the journal Nature Mental Health. They are the first publications based on the inaugural ...

“We could have a disaster on the scale of Japan 2011 or Sumatra 2004,” said Tina Dura, the study’s lead author and an associate professor of natural hazards at Virginia Tech. “It’s the ...

The study, published in the journal eBiomedicine, analyzed health data and found "everywhere chemicals" contributed to 368,764 or 13% of all heart disease deaths in 2018, among men and women ages ...

Comparing the life expectancy of people born from 1900 to 2000, a study published Monday found that in many southern states, life expectancy changed very little, especially for women. But in ...

In the first quarter, U.S. net sales for Eylea HD and Eylea decreased 26% year-over-year to $1.04 billion, including $307 million from Eylea HD. Also Read: FDA Sets The Countdown: Regeneron’s ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug ...

Eylea sales fell 26% to $1.04 billion amid pricing pressure and market share loss; Eylea HD saw increased volume. Don’t miss this list of 10 overlooked stocks—including one paying a 9% ...